



MelNet update

21 March 2022



Melanoma Summit

New Zealand 2022

Post-event information is now available on the [MelNet website](#). This includes replies to questions that were not answered at the Summit and a summary of the priorities for action.

Summit session recordings are available for registered delegates to view until 12 August. Please [email](#) us if you need your log-in details again.

MelNet Goodfellow Skin Lesion and Dermatoscopy virtual course | 25 March 2022

It's not too late to join Adjunct Associate Professor Amanda Oakley at this pre-symposium beginners' workshop, whether you own a dermatoscope or not. Using a series of regional, close-up and dermoscopic images, this 4-hour workshop will increase your confidence in the diagnosis of typical benign skin lesions.

[More information](#) [Register now](#)

7-year follow up of KEYNOTE 006: Pembrolizumab vs Ipilimumab in advanced melanoma

"7-year follow-up of KEYNOTE-006: Pembrolizumab versus Ipilimumab in advanced melanoma" presents results of seven years of follow-up of survival for participants enrolled in KEYNOTE-006, including those who consented to transition to the KEYNOTE-587 extension study (NCT03486873).

For more information click [here](#) or view the [poster](#) that was presented at the 18th International Congress of the Society for Melanoma Research on 28-31 October 2021.



Determine optimal surgical excision margin | MelMarT-II Trial

The MelMarT-II trial is a world-wide clinical trial, coordinated by [Melanoma and Skin Cancer Trials \(MASC Trials\)](#). It investigates whether there is a difference in disease-free survival for patients treated with either a 1cm or 2cm excision margin for stage II primary cutaneous melanoma. The trial is located across 28 sites in Australia, New Zealand, United Kingdom, USA, Canada, The Netherlands and Sweden.

[Find out more](#)



Covid-19 and Cancer Services Report up until end of December 2021 | by Te Aho o Te Kahu, the Cancer Control Agency

Te Aho o Te Kahu, the Cancer Control Agency monitors the impact of COVID-19 on cancer diagnostic and treatment services. The fourth report looks at the number of cancer diagnoses and treatments to end of December 2021, compared to the same time period in the previous year/s to understand if the 2021 COVID-19 lockdown has impacted cancer diagnosis and treatment, and created or exacerbated inequities.

[Report summary](#) [Read the report](#) [View the full series](#)

Recent releases

“Towards better treatment outcomes for Australians with skin keratinocyte cancers - time for the patient voice?”

A recent editorial publication in the Journal of Cancer Prevention and Current Research explains that Keratinocyte (skin) cancer is the most common form of human cancer, yet limited treatment advances have been made in the past 10 years and few quality clinical trials have been published. The article suggests that patient advocacy groups should collaborate with researchers and decision makers to develop better treatments and improve research quality, relevance and translation into practice.

[Read the article](#)

“New topical treatment trial offers hope to organ transplant recipients”

A new clinical trial is exploring whether a simple topical cream applied to the face can reduce incidences of skin cancer in organ transplant recipients; a group that’s up to 65 times more likely to develop skin cancer than the general public. The SiroSkin trial, coordinated by Melanoma and Skin Cancer Trials Ltd., is investigating whether topical Sirolimus can reduce the number of facial squamous cell carcinomas in patients who have undergone an organ transplant. SiroSkin’s Chief Investigator and head of The University of Queensland’s Experimental Dermatology Group, Professor Kiarash Khosrotehrani, says the trial could have dramatic implications for patients and healthcare systems around the world.

[Find out more](#)

“Are We Missing Something? The Skin Lesions Not Seen in Teledermatology”

MelNet Executive committee member Adjunct Associate Professor Amanda Oakley has been engaged in this study which aims to evaluate the number of skin cancers missed during teledermatology assessment. It concludes that single-lesion teledermoscopy diagnoses have high concordance with in-person evaluation and histology; however, in-person examination may reveal other suspicious lesions. The importance of a full-body skin examination should be emphasized to the referrer.

[Read the article](#)

“Artificial Intelligence Support for Skin Lesion Triage in Primary Care and Dermatology”

This study, also co-authored by Amanda Oakley, aimed to assess the reliability of an artificial intelligence (AI)-based clinical triage algorithm in classifying benign and malignant skin lesions and evaluate the quality of images obtained in primary care using the study camera (3Gen DermLite Cam v4 or similar). The study concludes that the AI algorithm demonstrates encouraging results, with high sensitivity and specificity, concordant with previous AI studies, and shows potential as a triage tool in conjunction with teledermatology to augment health care and improve access to dermatology.

[Read the article](#)

Upcoming opportunities and events

Masterclass with Harald Kittler

Join a 90-minute Skin Cancer Institute online Masterclass with Professor Harald Kittler who will present a number of challenging cases and discuss pitfalls, errors, common mistakes and published and unpublished clues.

When: Thursday, 24 March 2022

Time: 9.00pm – 11.00pm NZDT (6.00pm - 8.00pm AEDT)

Cost: Free of charge (introductory offer courtesy of Skin Cancer Institute)

[Register here](#)



The [18th EADO Congress](#) will be an on-site congress in Seville, Spain with additional virtual access, held on 21 – 23 April 2022. It has a clinical focus on both the early diagnosis of skin cancer and dermatosurgery as part of the integral approach to skin cancer patients. Early bird registration closes on 30 March.

Updates in skin cancer diagnosis and management: Hybrid GP education evening | on 28 April 2022

Melanoma Institute Australia is hosting a hybrid GP education evening featuring world-leading experts to provide updates for GPs in melanoma and complex non-melanoma skin cancers.

Programme:

- Early detection: Essential knowledge for GPs - Dr Annika Smith (Dermatologist)
- Surgical management of melanoma - A/Prof Alex van Akkooi (Surgeon)
- Surgical management of non-melanoma skin cancer - A/Prof Sydney Ch'ng (Surgeon)
- New developments in systemic treatment for early melanoma - Prof Georgina Long AO (Medical Oncologist)

The evening will conclude with a multidisciplinary case study panel discussion and Q&A.

Click [here](#) for more information and to register



Location:

Hybrid event in Sydney, Australia and online

Date:

Thursday 28 April 2022

8.30pm to 10.30pm NZST (6.30pm to 8.30pm AEST)



The [Australasian College of Dermatologists 2022 Annual Scientific Meeting](#) will be held in person in Adelaide on 30 April – 3 May 2022, with recorded on-demand content available after the meeting.

Other upcoming opportunities and events

April
Professional Certificate of Skin Cancer Medicine Professional Certificate of Skin Cancer Surgery Advanced Certificate of Skin Cancer Surgery 2 April 2022 Melbourne, Australia Find out more
Advanced Certificate of Skin Cancer Medicine Professional Diploma of Skin Cancer Surgery 3 April 2022 Melbourne, Australia Find out more
Professional Certificate of Skin Cancer Medicine Professional Certificate of Skin Cancer Surgery Advanced Certificate of Skin Cancer Surgery 9 April 2022 Brisbane, Australia Find out more
Advanced Certificate of Skin Cancer Medicine Professional Diploma of Skin Cancer Surgery 10 April 2022 Brisbane, Australia Find out more
Advanced Skin Surgery Workshop 29 April - 2 May 2022 Melbourne, Australia Find out more

May
RACS ASC 2022 2 – 6 May 2022 Brisbane, Australia Find out more
The 3rd Immuno-Oncology World Congress 12 – 13 May 2022 Copenhagen, Denmark Find out more
Melanoma Focus Virtual Regional Meeting 13 May 2022 Online Find out more
3rd Edition of International Conference on Dermatology and Cosmetology (IDC 2022) 18 – 19 May 2022 Hybrid Conference: Tokyo, Japan and Virtual Find out more
Australasian Skin Cancer Congress 20 – 22 May 2022 Hybrid Conference: Gold Coast and Virtual Find out more
For more events see the MelNet events calendar

Recent MelNet website postings

Below is a selection of recent **news postings** on the MelNet website. Please visit the [website](#) to view all the latest news items.

[Greater benefit of inhibition of two immune checkpoints, LAG-3 and PD-1, than PD-1 alone in patients with previously untreated metastatic or unresectable melanoma](#)

[Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance](#)

[Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients](#)

[Multispectral imaging algorithm predicts Breslow thickness of melanoma](#)

[Effectiveness of sun-safety education behaviour via spectrophotometric evaluation](#)

[Significant improvement of UV-related knowledge among Australian primary school students after short interactive educational activity using handheld UV dosimeters](#)

[Incidence and mortality of uveal melanoma in Australia \(1982–2014\)](#)

[Sentinel lymph node biopsy should be encouraged for all patients with clinical stage IB and II acral lentiginous melanoma](#)

[Perceived barriers and facilitators towards mobile health apps for skin cancer screening](#)

[Substantial activity and manageable toxicity of second line therapy with PD-1 inhibitors plus BRAF±MEK inhibitors for patients with metastatic melanoma](#)

[Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma](#)

[Bempegaldesleukin plus nivolumab in first-line metastatic melanoma tolerated with encouraging antitumour activity](#)

[Favourable outcomes of concurrent radiotherapy and immune checkpoint inhibitor therapy in melanoma brain metastasis patients](#)

[Oxidative stress-related mechanisms in melanoma and in the acquired resistance to targeted therapies](#)

[Female patients with advanced melanoma may not benefit as much from combination immune checkpoint inhibitors as male patients](#)



Support our work. Donate to MelNet



Join us on facebook